Pacira Biosciences, Inc. (PCRX)

Pacira BioSciences' stock price has been impacted by several events over the past six months. Q4 2025 earnings missed estimates, leading to a stock decline. Q1 2026 earnings per share missed estimates by a penny, though revenue exceeded expectations. An activist proxy battle with DOMA Perpetual Capital Management LLC has added a governance twist. Insiders have sold more company stock than they have bought. Pacira announced real-world Medicare data for EXPAREL, demonstrating reduced opioid use and lower total medical costs. Analysts have a "Hold" consensus rating for PCRX, with an average one-year target price of $29.40.

Demand for Pacira's products and services may experience some seasonality, with stronger performance typically observed in the late fall and early winter months. A seasonal chart analysis suggests a period of seasonal strength, with positive returns historically observed between November and February.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing non-opioid pain management and regenerative health solutions. The company's mission is to provide effective alternatives to opioids for pain management. Key products include EXPAREL, a long-acting local analgesic; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and the iovera° system, a non-opioid cryoanalgesia device. Pacira is also advancing its pipeline with PCRX-201, a gene therapy for osteoarthritis of the knee, and has a commercialization agreement for NOCITA, a bupivacaine liposome injectable suspension for animal use.

Pacira BioSciences primarily focuses on healthcare practitioners in the United States for the sale and distribution of its products. The company is also pursuing geographic expansion, including an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets.

Pacira BioSciences has established a reputation as an industry leader committed to delivering innovative, non-opioid pain therapies. The company's reputation has been influenced by an activist proxy battle and positive real-world data for EXPAREL, demonstrating reduced opioid use and lower medical costs. Advancements in gene therapy with PCRX-201 also contribute to its image as an innovative biopharmaceutical organization.

Pacira BioSciences' ownership is heavily influenced by institutional investors, who collectively hold a significant stake. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Doma Perpetual Capital Management LLC, and State Street Corp. Individual investors and company insiders also hold shares.